Lung cancer in the elderly: Current and future chemotherapeutic optionsHINTON, Stuart; SANDLER, Alan.Drugs & aging. 2002, Vol 19, Num 5, pp 365-375, issn 1170-229XArticle

Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung CancerHORN, Leora; SANDLER, Alan.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5040-5048, issn 1078-0432, 9 p.Article

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)CALLIES, Sophie; DE ALWIS, Dinesh P; WRIGHT, James G et al.Cancer chemotherapy and pharmacology. 2003, Vol 51, Num 2, pp 107-118, issn 0344-5704, 12 p.Article

Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II StudySCHILLER, Joan H; LARSON, Timothy; VON PAWEL, Joachim et al.Journal of clinical oncology. 2009, Vol 27, Num 23, pp 3836-3841, issn 0732-183X, 6 p.Article

Ongoing and future trials of biologic therapies in lung cancerBUNN, Paul A; SHEPHERD, Frances A; SANDLER, Alan et al.Lung cancer. 2003, Vol 41, pp S175-S186, issn 0169-5002, SUP1Conference Paper

Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II studyHANNA, Nasser; ANSARI, Rafat; FISHER, William et al.Lung cancer. 2002, Vol 35, Num 3, pp 293-297, issn 0169-5002Article

Non-small cell lung cancerLASKIN, Janessa J; SANDLER, Alan B; JOHNSON, David H et al.Seminars in oncology. 2005, Vol 32, Num 3, issn 0093-7754, 108 p.Serial Issue

Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II studyBHATIA, Sumeet; HANNA, Nasser; ANSARI, Rafat et al.Lung cancer. 2002, Vol 38, Num 1, pp 85-89, issn 0169-5002Article

Chemotherapy for small cell lung cancerSANDLER, Alan B.Seminars in oncology. 2003, Vol 30, Num 1, pp 9-25, issn 0093-7754, 17 p.Article

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non―Small Cell Lung CancerSOCINSKI, Mark A; GOLDMAN, Jonathan; BONOMI, Philip et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 3068-3077, issn 1078-0432, 10 p.Article

Development of Clinical Trials in a Cooperative Group Setting : The Eastern Cooperative Oncology GroupDILTS, David M; SANDLER, Alan; CHENG, Steven et al.Clinical cancer research. 2008, Vol 14, Num 11, pp 3427-3433, issn 1078-0432, 7 p.Article

Phase i study of inhaled doxorubicin for patients with metastatic tumors to the lungsOTTERSON, Gregory A; VILLALONA-CALERO, Miguel A; KRAUT, Michael et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1246-1252, issn 1078-0432, 7 p.Article

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCAO, Carolyn; ALBERT, Jeffrey M; LING GENG et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11409-11415, issn 0008-5472, 7 p.Article

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. EditorialSCHILLER, Joan H; HARRINGTON, David; BELANI, Chandra P et al.The New England journal of medicine. 2002, Vol 346, Num 2, pp 92-98, issn 0028-4793, 10 p.Article

Altretamine for the treatment of metastatic renal cell carcinoma : A Hoosier Oncology Group trialZON, Robin T; MCCLEAN, John; HELMAN, Douglas et al.Investigational new drugs. 2001, Vol 19, Num 3, pp 229-231, issn 0167-6997Article

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesSANDLER, Alan; HIRSH, Vera; RECK, Martin et al.Lung cancer. 2012, Vol 78, Num 1, pp 1-7, issn 0169-5002, 7 p.Article

Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung CancerBLUMENSCHEIN, George R; RECKAMP, Karen; STEPHENSON, G. Joe et al.Clinical cancer research (Print). 2010, Vol 16, Num 1, pp 279-290, issn 1078-0432, 12 p.Article

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyROBERT, Francisco; SANDLER, Alan; TRAYNOR, Anne M et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 4, pp 669-680, issn 0344-5704, 12 p.Article

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionMITA, Alain C; SWEENEY, Christopher J; MOLPUS, Kathleen et al.Journal of clinical oncology. 2006, Vol 24, Num 4, pp 552-562, issn 0732-183X, 11 p.Article

A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremitiesMUNDT, Arno J; VIJAYAKUMAR, Srinivasan; KESSLER, Paul D et al.Clinical cancer research. 2004, Vol 10, Num 17, pp 5747-5753, issn 1078-0432, 7 p.Article

A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancerBHATIA, Sumeet; HANNA, Nasser; ANSARI, Rafat et al.Lung cancer. 2002, Vol 38, Num 1, pp 73-77, issn 0169-5002Article

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and CelecoxibFIDLER, Mary J; ARGIRIS, Athanassios; BONOMI, Philip et al.Clinical cancer research. 2008, Vol 14, Num 7, pp 2088-2094, issn 1078-0432, 7 p.Article

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improvestumor growth delay in irradiated lung cancer modelsALBERT, Jeffrey M; CAO, Carolyn; LOW, Jennifer et al.Clinical cancer research. 2007, Vol 13, Num 10, pp 3033-3042, issn 1078-0432, 10 p.Article

Bevacizumab in non-small cell lung cancer. DiscussionSANDLER, Alan; LYNCH, Thomas; HERBST, Roy et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4613s-4616s, 2Conference Paper

Combining targeted agents : Blocking the epidermal growth factor and vascular endothelial growth factor pathwaysSANDLER, Alan; HERBST, Roy.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4421s-4425s, 2Conference Paper